Candel Therapeutics Inc (NASDAQ: CADL) kicked off on Tuesday, down -7.83% from the previous trading day, before settling in for the closing price of $4.98. Over the past 52 weeks, CADL has traded in a range of $3.79-$14.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -20.00% over the last five years. While this was happening, its average annual earnings per share was recorded 13.60%. With a float of $34.58 million, this company’s outstanding shares have now reached $46.93 million.
The firm has a total of 38 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Candel Therapeutics Inc (CADL) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Candel Therapeutics Inc is 26.79%, while institutional ownership is 35.14%. The most recent insider transaction that took place on Mar 18 ’25, was worth 396,995. In this transaction Chief Medical Officer of this company sold 45,316 shares at a rate of $8.76, taking the stock ownership to the 52,493 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Scientific Officer sold 32,146 for $8.76, making the entire transaction worth $281,673. This insider now owns 96,527 shares in total.
Candel Therapeutics Inc (CADL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.34% during the next five years compared to -43.86% drop over the previous five years of trading.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Take a look at Candel Therapeutics Inc’s (CADL) current performance indicators. Last quarter, stock had a quick ratio of 2.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.75, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.87 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Analysing the last 5-days average volume posted by the [Candel Therapeutics Inc, CADL], we can find that recorded value of 0.94 million was lower than the volume posted last year of 1.17 million. As of the previous 9 days, the stock’s Stochastic %D was 48.79%. Additionally, its Average True Range was 0.45.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 3.29%, which indicates a significant decrease from 19.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.82% in the past 14 days, which was lower than the 163.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.48, while its 200-day Moving Average is $6.54. Now, the first resistance to watch is $4.88. This is followed by the second major resistance level at $5.17. The third major resistance level sits at $5.36. If the price goes on to break the first support level at $4.40, it is likely to go to the next support level at $4.21. Should the price break the second support level, the third support level stands at $3.92.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
The company with the Market Capitalisation of 216.81 million has total of 49,270K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -55,180 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -14,070 K.
